CD274 and non-small cell lung carcinoma: Particularly to date we have three monoclonal antibodies (MoAbs), Nivolumab, Pembrolizumab and Atezolizumab, targeting the programmed cell death 1 (PD1)/programmed cell death 1 ligand (PD-L1) immune-checkpoint, approved by regulatory authorities for the treatment of advanced NSCLC [3].